Skip to content

Breaking News


Immune Regulation Ltd., which does business as Revolo Biotherapeutics, has hired CordenPharma Boulder Inc. to produce doses of its lead anti-allergy drug candidate ahead of Phase II trials.

Revolo’s drug candidate, dubbed ‘1104, targets a condition that leads to allergic reactions and inflammation of the organs that connect the mouth to the stomach. The company’s drug candidate pipeline focuses on immune system modulation for chronic conditions such as rheumatoid arthritis and esophagitis.

Revolo plans to start trials of the drug candidate by the end of the year, and the active ingredients for those doses will be produced at CordenPharma’s Boulder plant. It did not respond to a BizWest request for comment on how many doses will be produced, or how much the deal is worth financially to CordenPharma.

The company is also conducting a small-scale safety trial to determine if ‘1104 could be used as a treatment for COVID-19. Some researchers have suggested that several cases of severe COVID-19 are caused by an overactive immune system causing undue harm to healthy tissue.

Other nearby companies such as Fort Collins’ Cytocom Inc. and Westminster’s Arca Biopharma Inc. (Nasdaq: ABIO) are developing their own COVID-19 treatments that aim to modulate immune responses in patients.

CordenPharma is also producing lipids on behalf of Moderna Inc. (Nasdaq: MRNA) as part of that company’s COVID-19 vaccine.

Revolo has offices in New Orleans and near Cambridge, England.

© 2021 BizWest Media LLC